Change in Control Severance AgreementChange in Control • March 4th, 2022 • Treace Medical Concepts, Inc. • Surgical & medical instruments & apparatus • Florida
Contract Type FiledMarch 4th, 2022 Company Industry JurisdictionThis CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of October 25, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and SCOT M. ELDER (the “Executive”).
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control • April 19th, 2021 • Treace Medical Concepts, Inc. • Surgical & medical instruments & apparatus • Florida
Contract Type FiledApril 19th, 2021 Company Industry JurisdictionThis CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of April 19, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and John T. Treace (the “Executive”).
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control • April 19th, 2021 • Treace Medical Concepts, Inc. • Surgical & medical instruments & apparatus • Florida
Contract Type FiledApril 19th, 2021 Company Industry JurisdictionThis CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of April 19, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and Jaime A. Frias (the “Executive”).
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control • April 19th, 2021 • Treace Medical Concepts, Inc. • Surgical & medical instruments & apparatus • Florida
Contract Type FiledApril 19th, 2021 Company Industry JurisdictionThis CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of April 19, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and MARK L. HAIR (the “Executive”).
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control • February 12th, 2021 • Treace Medical Concepts, Inc. • Surgical & medical instruments & apparatus • Florida
Contract Type FiledFebruary 12th, 2021 Company Industry JurisdictionThis CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of October 5, 2020, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and Jaime A. Frias (the “Executive”).